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Abstract
Background—Prostate-specific antigen (PSA) detected in vaginal fluid can be used in studies of 
HIV/sexually transmitted infection (STI) and pregnancy prevention as an alternative to relying on 
participant reports of exposure to semen. Optimal methods for collecting and storing specimens 
for this testing have not been determined.
Study Design—We conducted a controlled, in vitro experiment of 550 specimens spiked with 
semen to determine the effects of swab type (five types), storage conditions of the swabs (room 
temperature with or without desiccant or at −80°C without desiccant) and time from collection to 
testing (seven intervals over the course of 12 months) on the identification of PSA. We performed 
factorial analysis of variance to identify factors influencing PSA detection.
Results—Concentrations of PSA detected in the swabs declined with time of storage over the 1-
year experiment (p<.01). The 1-mL, rayon-tipped swab stored immediately at −80°C following 
collection performed best.
Conclusions—If immediate testing or freezer storage is not feasible, investigators should use a 
swab with 1-mL capacity with processing and testing as soon as possible after specimen 
collection.
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1. Introduction
Prostate-specific antigen (PSA) has long been used in sexual assault cases as a highly 
sensitive and specific method of determining the presence of semen [1–4]. More recently, 
the identification of PSA has been used in studies of HIV/ sexually transmitted infection 
(STI) and pregnancy prevention as an alternative to relying on participant reports of 
exposure to semen, which are not always accurate [5]. For example, the effectiveness of 
male and female condoms in protecting against exposure to semen can be evaluated by 
comparing levels of PSA detected in pre- and postcoital vaginal swabs [6–9]. This objective 
measurement of the woman’s exposure to semen represents a methodological improvement 
by reducing the potential for intentional or unintentional (e.g., from undetected condom 
malfunctions) misreporting of condom effectiveness. PSA also could be used to monitor 
changes in condom use following the introduction of interventions to prevent HIV (e.g., 
circumcision or microbicide use). Furthermore, studies on the role of hormonal 
contraception on HIV acquisition and transmission could test for the biomarker in order to 
identify differences between study arms in their underlying risk of HIV.
Evidence from forensic science suggests that PSA is a relatively stable protein; the marker 
has been detected in dried samples stored up to 30 years at room temperature [1]. 
Sensabaugh [4], though, did not detect PSA as consistently in vaginal washings as in semen 
stains on material, possibly because the overall concentration of PSA was much greater in 
stains than when it had been diluted in vaginal fluid. Given the greater flexibility in the 
collection and storage of specimens in clinical research than in forensic casework, 
determining the optimal procedures for storing vaginal specimens is feasible for improving 
the use of PSA as a biomarker in clinical trials.
2. Materials and methods
2.1. Overall
We conducted a 1-year, controlled, in vitro experiment to determine the ideal conditions for 
collecting and storing vaginal swabs for PSA testing. We evaluated the performance of five 
swabs: three that have been used in quantitative testing for PSA in research studies [Puritan,
2
 #808 (Fisher), Falcon Swube Collection and Transport System, #220210 (Becton 
Dickinson and Co.), BBL CultureSwabs, #220135 (Becton Dickinson)], one that has been 
used for testing for Y-chromosome deoxyribonucleic acid [Starswab II, #S09D (Starplex 
Scientific)] and a newer swab with a breathable filter [FAB-SWAB, #SW3B400 (Abacus 
Diagnostics)] (Table 1). We also evaluated the effect of duration of storage (i.e., 1 day, 1 or 
2 weeks or 1, 3, 6 or 12 months) and temperature (i.e., room temperature with or without 
desiccant or at −80°C without desiccant). We spiked five swabs for each condition to be 
tested with pooled semen remnants from anonymous donors at a health clinic. We also 
tested five swabs of each type immediately after their preparation (Day 0). Thus, we 
prepared and tested a total of 550 swabs.
2Use of trade names is for identification only and does not imply endorsement by the US Department of Health and Human Services.
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2.2. Laboratory procedures
A single technician performed all laboratory procedures. After allowing male semen stock to 
sit at room temperature until visibly thawed (about 10 min), we diluted it at a 1:1000 ratio 
with a 95:5 ratio mixture of phosphate buffer saline (PBS; 0.1M, pH 7.2) and polysorbate 20 
(Tween 20). The resulting mixture had a mean of 569.8 ng/mL of total PSA. Using a 
calibrated pipette, we applied a sufficient quantity of the semen and buffer mixture to the 
swabs so that each swab received approximately the volume of its capacity. (For example, 
the Puritan swab received 1 mL of the semen mixture.) We placed each swab into its tube, 
which was then placed into an individual, sealable plastic bag. For the Puritan, CultureSwab, 
Starswab and FAB-SWAB swabs that were to be stored with desiccant, we placed two 
desiccant packets (MiniPax Sorbent; Multisorb technologies, Buffalo, NY, USA) into each 
plastic bag. For the Swube, we used a glass stirring rod to push a desiccant packet into the 
bottom of the tube before the swab was inserted. The sealed bags were stored in either a 
−80°C freezer or at room temperature for 1 day, 1 or 2 weeks or 1, 3, 6 or 12 months.
At the specified time for extraction and testing, we inserted the vaginal swab into a 15-mL 
Falcon conical tube containing PBS/Tween 20 (95:5 ratio) in an amount three times that of 
the capacity of the specific swab. After the swab contents eluted into the buffer at room 
temperature for 20–30 min, we vortexed the swab for about 10 s to dislodge any material 
from the swab tip and then vigorously rotated and pressed the swab against the side of the 
tube to maximize sample recovery. After vortexing the extraction tubes for a few seconds, 
we pipetted 300 μL of the resulting eluent into a sample cup. Following the manufacturer’s 
published protocol, we tested the specimens using ARCHITECT assays for total PSA and 
free PSA (Abbott Diagnostics, Abbott Park, IL, USA). Any samples that exceeded the 
detection limit of the assays for total and free PSA (100 and 30 ng of PSA per mL, 
respectively) were diluted with the PBS/Tween 20 buffer and retested to quantify 
concentrations above these levels. Because the differences in results between the assays for 
total and free PSA were slight and did not change any of the conclusions from the analysis 
of variance (ANOVA) analyses, we report only the total PSA.
We discarded the specimens after testing except for the eluent from the testing of the Puritan 
swabs at baseline, 1 day and 6 months. (The Puritan swab was the only swab with sufficient 
residual eluent to permit additional testing.) The residual eluents were stored in cryovials at 
−80° for rethawing and retesting at subsequent testing times (followed by immediate 
refreezing).
2.3. Statistical analysis
We performed factorial ANOVA to examine the effects of time, swab type, storage 
condition and their respective interactions on the quantitative measure of PSA. Because the 
PSA values had a skewed distribution, we used the logarithm of the values as the dependent 
outcome in the modeling. For factors with a significant F value (p<.05), we used the Tukey 
Range Test to evaluate whether the means of each level of the factor differed significantly 
from one another [10].
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3. Results
The effects of time, swab types, storage conditions and their respective interactions 
explained most of the variation in the total PSA detected (R2=.86, factorial ANOVA). The 
amount of PSA detected in the stored swabs declined over time irrespective of the swab type 
or the storage condition (p<.01; Table 2, Fig. 1A–1E). The swabs differed in their 
performances (p<.01) with the Puritan swab yielding the most total PSA (geometric mean, 
38.8 ng/mL) followed by the Swube (22.0 ng/mL), the CultureSwab (4.3 ng/mL), the FAB-
SWAB (3.7 ng/mL) and the Starswab (2.0 ng/mL). The performances of the five swabs were 
all statistically significantly different from each other except for the comparison between the 
CultureSwab and the FAB-SWAB.
The three storage conditions resulted in differences in the detection of total PSA (p<.01). 
The immediate storage of swabs at −80°C until the time of their processing and testing 
yielded the highest concentrations of the marker (geometric mean, 28.8 ng/mL). The use of 
desiccant resulted in higher PSA concentrations for the swabs stored at room temperature 
(geometric mean, 5.0 ng/mL vs. 3.2 ng/mL for those without desiccant).
Repeated cycles of freezing the eluent followed by its thawing and retesting affected the 
ability to detect PSA in the Puritan swabs (Table 3; Fig. 2A–2B). Among the residual 
eluents stored in the freezer following their initial testing on Day 1, the concentrations of 
PSA differed between the thawing and retesting at 3 and 6 months (p<.03). The eluents 
stored in the freezer following their initial testing at 6 months resulted in lower 
concentrations of PSA detected at 12 months (p<.01). The swabs stored at room temperature 
(with or without desiccant) before their initial testing fared worse than those stored in the 
freezer before their initial testing (p<.01).
4. Discussion
Semen biomarkers could improve our ability to measure and control for sexual behavior in 
studies of contraception and HIV/STIs. The use of PSA in research would be improved by 
standardizing the methods for collecting and storing specimens for this testing. The present 
in vitro experiment revealed that the concentration of PSA detected declined over time, that 
the swab with the largest capacity performed best and that storage at −80°C was preferable 
over room temperature storage. This last finding is consistent with evidence suggesting that 
freezer is superior to room temperature storage for detection of free PSA in serum [11].
PSA exists in serum in several forms: complexed to alpha-1-anti-chymotrypsin, unbound 
(free PSA) and enveloped by alpha-2-macroglobulin (which is not detected by 
immunoassays) [12]. The Abbott assay for total PSA is optimized to detect a mixture of the 
first two forms. PSA in semen, though, is almost exclusively present in free form [13,14]. 
Consequently, the Abbott assay for total PSA (designed to detect PSA in blood) tended to 
result in lower concentrations for PSA than the assay for free PSA (data not reported). 
However, the differences between assays were slight, and testing for total PSA still could be 
preferred for several reasons including (a) its lower cost; (b) its higher limit of detection 
(which results in less laboratory burden required for the dilution and retesting of specimens) 
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and (c) its use in previous studies of PSA detection for prevention of pregnancy or HIV/STIs 
[6–9], which facilitates comparisons across studies.
The Puritan swab may have performed better because of its greater 1-mL capacity compared 
to the other swabs, which have capacities ranging 150–225 μL. That is, the larger size of the 
Puritan swab head might have allowed it to capture more PSA when the specimen was 
prepared. The second largest swab tested, CultureSwab, performed about the same as the 
Puritan swab when stored in the freezer. In contrast to the effect of the swab capacity, the 
effect of the swab material on its performance was not evident. For example, while both the 
Puritan and the Starswab swabs are comprised of rayon, the Starswab resulted in the lowest 
average concentration of PSA detected.
The main limitation of the findings is that they are the result of in vitro research only using 
spiked swabs. Vaginal specimens collected from women following semen exposure might 
yield different PSA test results. However, we spiked the specimens with semen stock diluted 
with a buffer mixture in a ratio designed to approximate the dilution of semen that might 
occur in the vaginal cavity. The experiment also did not evaluate other vaginal products 
(e.g., lubricants or gels) or factors (e.g., menstruation or vaginal cleansing) that possibly 
could influence the clearance or detection of PSA in vaginal fluid specimens and could 
interact with swab types differently. Finally, other questions related to the laboratory 
processes remain unanswered. Because −20°C storage is more feasible for many clinics than 
−80°C storage, determining whether the two storage temperatures have a similar effect on 
the specimens would be helpful. In addition, it is unknown whether processing the 
specimens immediately and storing the eluent (rather than the swab) for later testing for PSA 
would yield similar results.
In summary, this in vitro study suggests that 1-mL swabs are optimal for PSA detection; 
swabs with lower capacities are not recommended. Swabs should be immediately tested or 
stored at −80°C following their collection. If neither of these is feasible, investigators should 
process and test the swabs as soon as possible.
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Fig. 1. 
(A–E). Mean total PSA by swab type and storage condition.
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Fig. 2. 
(A–B). Mean total PSA detected from “Puritan” swabs after repeated freezing and thawing 
cycles.
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Table 1
Types of swabs evaluated
Swab Product name (manufacturer) Specifications
Studies 
using the 
swab
Puritan Puritan, #808 (Fisher) 1-mL, rayon-tipped swab used with a custom cardboard 
tampon-like applicator
[6–9]
“Swube” Falcon Swube Collection and Transport System, 
#220210 (Becton Dickinson and Co.)
150-μL cotton-tipped swab in a screw-cap tube [15–19]
“CultureSwab” BBL CultureSwabs, #220135 (Becton 
Dickinson)
Two 225-μL, polyester-tipped swabs on plastic 
applicators that fit into a single tube cap
[20]
“FAB-SWAB” FAB-SWAB, #SW3B400 (Abacus Diagnostics) 175-μL, cotton-tipped swab with a built-in Tyvek® 
breathable filter
“Starswab” Starswab II, #S09D (Starplex Scientific) Two 125-μL rayon-tipped swabs on plastic applicators 
that fit into a single tube cap
[21–26]
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Table 3
Mean total PSA detected from Puritan swabs after repeated freezing and thawing cycles
Storage Time of testing
First test At first freeze/thaw 
at 3 months
At second freeze/
thaw at 6 months
At fourth a freeze/
thaw at 12 months
First tested on Day 0 91.4 75.8 86.6 81.4
Stored at room temperature without desiccant before 
first testing on Day 1
50.3 46.8 50.9 49.0
Stored at room temperature with desiccant before first 
testing on Day 1
49.0 46.4 53.1 49.5
Stored at −80°C before first testing on Day 1 86.6 77.1 84.0 77.3
Storage Time of testing
First test At first freeze/thaw after 12 months
Stored at room temperature without desiccant before first testing on Month 6 22.0 11.1
Stored at room temperature with desiccant before first testing on Month 6 28.7 16.6
Stored at −80°C before first testing on Month 6 55.4 46.2
a
Data from third freeze/thaw cycle not available.
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